In our study, a machine learning algorithm predicted that CCNA2 may be one of the key driving factors for the transformation of primary prostate cancer to CRPC, and virtual screening predicted that Aprepitant and CCNA2 protein have strong binding ability. The gene discussed is CCNA2; the disease is prostate carcinoma.